finance.yahoo.com

GSK Secures Japan Approval for Hibsago and FDA Priority Review for Jemperli

GSK plc logoGSK plc
Sig3.35Sen+4.10Env0.00Soc+3.70Gov0.00

GSK reports two regulatory milestones: Hibsago has secured its first approval in Japan as the first and only treatment described as delivering a functional cure for chronic hepatitis B. It blocks viral DNA replication and lowers hepatitis B surface antigen to support longer-lasting control for some patients. Separately, the FDA granted priority review for Jemperli for locally advanced rectal cancer, which remains under review.

Coverage (1)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro